Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
This study is testing a targeted medication called avapritinib to see if it can help patients with advanced solid tumors that have specific genetic changes called CKIT or PDGFRA mutations. The goal is to see if this medicine can block the signals that help cancer cells grow and spread.
You may be able to join if you are 12 or older, have an advanced solid tumor that has not responded well to standard treatments, and your tumor has the specific genetic mutations this study is looking for. Certain conditions, like specific heart issues or having a gastrointestinal stromal tumor (GIST), mean you cannot join.
If you join, you will receive the study medication avapritinib, which is designed to block specific enzymes that cancer cells need to grow. Your health care team will closely monitor your health, how your body responds to the treatment, and any side effects you might experience.
This study is currently recruiting participants and takes place in Houston, Texas, United States. Your care team can help you find out if this location works for you.
- 1Testing a targeted cancer medicine called avapritinib
- 2For patients with advanced solid tumors and specific genetic mutations
- 3Currently recruiting participants in Houston, Texas
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.